Physician profile
Lisa Pathak
NPI 1609868314
$5,442.15
in general payments reported to CMS, 2019-2025
26 companies · $636 in 2025
The $636 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $836 · 2020: $436 · 2021: $817 · 2022: $648 · 2023: $979 · 2024: $1,090 · 2025: $636.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,705.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,705.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,130.48 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,084.73 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $656.68 | 2019-2025 | Jardiance, Mounjaro |
| Radius Health, INC. | $436.97 | 2019-2025 | Tymlos |
| Abbvie INC. | $284.24 | 2021-2024 | |
| Amgen INC. | $275.79 | 2019-2025 | Otezla, Repatha, Evenity |
| Merck Sharp & Dohme LLC | $229.93 | 2019-2025 | Vaxelis, Vaxneuvance, Gardasil |
| Pfizer INC. | $203.00 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $167.46 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $161.64 | 2019-2025 | Spravato |
| Glaxosmithkline, LLC. | $153.57 | 2020-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $134.70 | 2020-2025 | Jardiance, Tradjenta |
| Abbott Laboratories | $111.13 | 2023-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Kowa Pharmaceuticals America, INC. | $75.40 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $46.13 | 2019-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $45.78 | 2023-2024 | Cologuard Collection Kit |
| Organon LLC | $38.14 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $37.35 | 2019-2021 | |
| Dexcom, INC. | $33.53 | 2025 | Dexcom G6 Transmitter |
| Sanofi Pasteur INC. | $28.24 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.60 | 2025 | Caplyta |
| Allergan, INC. | $18.48 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.33 | 2022 | |
| Xeris Pharmaceuticals, INC. | $16.76 | 2024 | Gvoke Hypopen |
| Eisai INC. | $14.72 | 2024 | |
| Tandem Diabetes Care, INC. | $14.37 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Pathak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.